The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy

Samantha Cox a,⁎,1, Christopher Hurt b,1, Tal Grenader c, Somnath Mukherjee d, John Bridgewater e, Thomas Crosby a

⁎ Corresponding author at: Department of Oncology, Velindre Cancer Centre, Cardiff CF14 2TL, United Kingdom.
E-mail addresses: samantha.cox@wales.nhs.uk (S. Cox), HurtCN@cardiff.ac.uk (C. Hurt), talgrenader65@hotmail.com (T. Grenader), Somnath.Mukherjee@oncology.ox.ac.uk (S. Mukherjee), j.bridgewater@ucl.ac.uk (J. Bridgewater), tom.crosby@wales.nhs.uk (T. Crosby).
1 Joint first authors.

Background and purpose: The derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dNLR in patients recruited to the SCOPE1 trial.

Materials and methods: 258 patients were randomised to receive dCRT ± cetuximab. Kaplan–Meier’s curves and both univariable and multivariable Cox regression models were calculated for overall survival (OS), progression free survival (PFS), local PFS inside the radiation volume (LPFSi), local PFS outside the radiation volume (LPFSo), and distant PFS (DPFS).

Results: An elevated pre-treatment dNLR ≥ 2 was significantly associated with decreased OS in univariable (HR 1.74 [95% CI 1.29–2.35], p < 0.001) and multivariable analyses (HR 1.64 [1.17–2.29], p = 0.004). Median OS was 36 months (95% CI 27.8–42.4) if dNLR < 2 and 18.4 months (95% CI 14.1–24.9) if dNLR ≥ 2. All measures of PFS were also significantly reduced with an elevated dNLR. dNLR was prognostic for OS in cases of squamous cell carcinoma with a non-significant trend for adenocarcinoma/undifferentiated tumours.

Conclusions: An elevated pre-treatment dNLR may be an independent prognostic biomarker for OS and PFS in oesophageal cancer patients treated with definitive CRT. dNLR is a simple, inexpensive and readily available tool for risk-stratification and should be considered for use in future oesophageal cancer clinical trials.

The SCOPE1 trial was an International Standard Randomised Controlled Trial [number 47718479].

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
and a number of inflammatory markers have been investigated as prognostic indicators in cancer patients [10,11].

One such biomarker, the neutrophil–lymphocyte ratio (NLR), has been associated with reduced survival in many solid tumours [12,13]. As the differential white cell count is regularly performed in the management of cancer patients, NLR is a relatively simple and inexpensive biomarker to implement in routine clinical practice. However it is a usual practice to only record total white blood cell (WBC) count and absolute neutrophil count (ANC) in trial databases, which may restrict the wider use of NLR in the clinical trial setting. As a result a modified version, the derived NLR (dNLR), has been developed using WBC and ANC parameters and is reported to have a similar prognostic value to NLR, using an optimal cut-off value ≥2:1 [14].

In this study, we investigated the prognostic value of dNLR on progression-free survival (PFS) and overall survival (OS) in oesophageal cancer patients treated with dCRT in the SCOPE1 (Study of Chemoradiotherapy in Oesophageal Cancer with or without Erbitux) trial. We also aimed to identify the optimal dNLR cut-off value in this patient group.

Materials and methods

Study design and setting

The primary objective of the randomised (1:1) phase 2/3 SCOPE1 study was to compare the effect of CRT with and without cetuximab on survival in patients with oesophageal cancer deemed unsuitable for surgery. 258 patients were recruited from 36 centres in the UK between February 2008 and January 2012. The CRT regimen consisted of 2 cycles of induction cisplatin–capecitabine chemotherapy followed by a further 2 cycles given concurrently with conformal external beam radiotherapy (50 Gy in 25 fractions over 5 weeks) with or without 12 weeks of cetuximab. The SCOPE1 adhered to the rules of CONSORT; the trial design, eligibility criteria and results have been reported previously [3,15]. Written informed consent was obtained from all recruited patients. A blood sample was taken in the week prior to starting treatment in all patients enrolled to the trial; WBC and ANC were documented on the case report form.

Statistical methods

All statistical analyses were pre-planned and conducted using Stata SE 14. We calculated % of total dose (actual total dose divided by protocol total dose) and % dose intensity (actual dose intensity [dose per unit time] divided by protocol dose intensity) for each protocol drug as measures of compliance. As has been done elsewhere, patients who progressed or died during the treatment period had denominators calculated up to the point where they progressed or died [16]. Likewise for radiotherapy we calculated % of full protocol dose received by each patient and for those who progressed or died during the treatment period the denominator was calculated up to the point where they progressed or died.

A derived neutrophil to lymphocyte ratio was calculated using the formula [14]:

\[ \text{dNLR} = \frac{\text{ANC}}{\text{WBC} - \text{ANC}} \]

dNLR was redefined as a binary variable by finding the value from a receiver-operating characteristic (ROC) curve that maximised the percentage correctly classified for predicting survival at 24 months (the median OS found in the first analysis of SCOPE1 [3]). The balance of this binary dNLR variable across prognostic characteristics of the SCOPE1 patients was assessed using chi square tests. Kaplan–Meier’s curves were used to display the prognostic value of the binary dNLR variable for different types of survival measure: overall survival (OS), progression free survival (PFS), local progression free survival inside the radiation volume (LPFSi), local progression free survival outside the radiation volume (LPFSo), and distant progression free survival (DPFS). We calculated survival from date of randomisation to when an event occurred i.e. progression or any death for PFS, and any death for overall survival. Patients who were event free were censored at the time they were last known to be event free. Univariable (the binary dNLR) and multivariable Cox regression models were used to assess the prognostic effect of dNLR on the different types of survival at two time points – pre-treatment (baseline) and following two cycles of induction chemotherapy prior to dCRT. The multivariable models included, in addition to the binary dNLR, SCOPE1 trial arm, age, reason for not receiving surgery, sex, WHO performance status at baseline, disease stage, tumour type, radiation compliance, cisplatin compliance, capecitabine compliance, and total disease length as covariates, and treating centre as a shared frailty. Additionally, a Cox model with a treatment–dNLR level interaction was used to assess whether the treatment effect differed between the two dNLR groups. In each case, the validity of the proportional hazards assumption was checked using Cox–Snell’s residuals and Schoenfeld’s global test.

Results

Of the 258 patients recruited into the SCOPE1 trial between February 2008 and February 2012, 257 had both pre-treatment WBC and ANC results collected and were used in these analyses. The median follow-up (iQR) was 46.2 (35.9–48.3) months for surviving patients. The distribution of dNLR was positively skewed with a median of 1.86 (iQR: 1.46–2.43, range: 0.75–26.00). The ROC analysis of the sensitivity and specificity of dNLR in predicting death within 24 months after randomisation was performed on 250 (97.2%) patients (1 patient did not have a pre-treatment dNLR available and a further 7 were lost to follow-up prior to 24 months) (Supplemental material, Fig. S1). Using ROC curve analysis, the optimal dNLR cut-off value was calculated as 2.029 (sensitivity = 55.75%, specificity = 70.07%) (Supplemental material, Fig. S1).

Patient and tumour baseline characteristics according to dNLR (<2 vs. ≥2) are shown in Table 1. Of the clinicopathological features analysed, sex, performance status, and total disease length were significantly associated with pre-treatment dNLR. However, if using a Bonferroni correction (p = 0.05/11 = 0.005), only sex was significantly associated with dNLR.

Kaplan–Meier’s curves according to the pre-treatment dNLR demonstrated a survival advantage for patients with dNLR < 2 (Fig. 1). Median OS was 36 months (95% CI 27.8–42.4) for patients with dNLR < 2 and 18.4 months (95% CI 14.1–24.9) for patients with dNLR ≥ 2. An elevated dNLR ≥ 2 was significantly associated with a decreased OS in both univariable analysis (HR 1.74 [95% CI 1.29–2.35], p = 0.005) and multivariable analysis (HR 1.64 [1.17–2.29], p = 0.004) (Table 2). In subgroup analysis, dNLR ≥ 2 was an independent prognostic factor for poor OS in patients with squamous cell carcinoma (HR = 2.06, 95% CI: 1.25–3.41, p = 0.005) but the evidence was weaker for adenocarcinoma/undifferentiated tumours (HR = 2.52, 95% CI: 0.88–7.23, p = 0.085) for whom the sample size was smaller (Supplemental material, Table S1).

In the analysis of OS according to arm allocation within the SCOPE1 trial, dNLR was not predictive for treatment effect (Fig. 2, Table 3). The addition of cetuximab to CRT was not associated with...
a survival difference for patients in either dNLR groups, with a p-value for interaction of 0.768.

We repeated the multivariable analyses in a sensitivity analysis that excluded patients who died during treatment (6 patients) and the findings above were unchanged.

The prognostic value of a repeat dNLR following 2 cycles of induction chemotherapy but prior to the commencement of dCRT was also analysed. Of the 258 patients, 7 were lost to follow up prior to 2 years and 36 had missing pre-CRT WBC or ANC results, leaving 215 in the analysis. The distribution of dNLR at this time point was positively skewed with a median of 1.19 (IQR: 0.85–4.86). Using ROC curve analysis, the optimal dNLR cut-off value to be 2, externally validating this threshold level.

The prognostic value of dNLR has since been investigated in several malignancies including breast [18], urological [19], colorectal [20], and upper gastrointestinal tumours [21–23]. However to our knowledge, our study is the first to investigate the prognostic role of dNLR in oesophageal cancer.

There is evidence for the use of NLR as a prognostic indicator of survival in oesophageal cancer. A meta-analysis of over 1500 patients from seven retrospective cohort studies confirmed that an elevated pre-treatment NLR was prognostic for OS but not disease-free survival [24]. T3–4 disease and lymph node disease were also significantly associated with NLR. However the study included pooled data from largely Asian, retrospective surgical series which included the use of both neoadjuvant and adjuvant CRT, resulting in significant between-study heterogeneity. Furthermore, the studies included employed a variety of NLR cut-off values ranging between two and five.

The only study to evaluate NLR in oesophageal cancer patients treated with definitive CRT confirmed that a raised NLR was an independent prognostic factor for both OS and PFS in 138 patients [25]. The patient population was similar to that of our study, the majority having locally-advanced, predominantly inoperable squamous cell carcinoma. However it was a retrospective study, there were significant differences in the chemotherapy regimens used and radiotherapy included treating both the primary and involved nodes up to a total dose of 63 Gy with considerably larger target volume margins and regional elective nodal irradiation. Furthermore, the median OS for all patients was significantly lower than that of the SCOPE1 trial, reported at only 19.9 months (range 1.1–97.2) [25]. Despite these differences in regimens and OS between cohorts, NLR proved to be discriminatory in both the

---

### Table 1

Characteristics of the study participants, according to baseline dNLR level.

|                      | dNLR < 2 (n = 146) | dNLR ≥ 2 (n = 111) | Test |
|----------------------|-------------------|-------------------|------|
| **dCRT arm**         |                   |                   |      |
| dCRT only            | 74                | 50.7              |      |
| dCRT + cetuximab     | 72                | 49.3              |      |
| **Age**              |                   |                   |      |
| <65                  | 65                | 44.5              |      |
| ≥65                  | 81                | 55.5              |      |
| **Reason for not receiving surgery** |                   |                   |      |
| Patient choice       | 59                | 40.4              |      |
| Local extent of disease | 68                | 46.6              |      |
| Comorbid/poor PS     | 19                | 13.0              |      |
| **Sex**              |                   |                   |      |
| Female               | 77                | 52.7              |      |
| Male                 | 69                | 47.3              |      |
| **WHO performance status** |                 |                   |      |
| 0                    | 83                | 56.8              |      |
| 1                    | 63                | 43.2              |      |
| **Stage**            |                   |                   |      |
| I or II              | 64                | 43.8              |      |
| III                  | 82                | 56.2              |      |
| **Tumour type**      |                   |                   |      |
| Squamous             | 111               | 76.0              |      |
| Adeno/undiff         | 35                | 24.0              |      |
| **Full radiation dose** |                 |                   |      |
| Yes                  | 129               | 88.4              |      |
| No                   | 17                | 11.6              |      |
| **Cisplatin intensity** |                 |                   |      |
| ≥75%                 | 107               | 73.3              |      |
| <75%                 | 39                | 26.7              |      |
| **Cape/5FU intensity** |                 |                   |      |
| ≥75%                 | 103               | 70.6              |      |
| <75%                 | 43                | 29.5              |      |
| **Total disease length** |                |                   |      |
| <4 cm                | 30                | 20.5              |      |
| ≥4 to <6 cm          | 59                | 40.4              |      |
| ≥6 to <8 cm          | 26                | 17.8              |      |
| ≥8 cm                | 31                | 21.2              |      |

(dNLR: derived neutrophil–lymphocyte ratio; dCRT: definitive chemoradiotherapy; WHO: World Health Organisation).

* Chi square test for trend.
a. Overall survival

b. Progression free survival

c. Local progression free survival (in RT volume)

d. Local progression free survival (out of RT volume)

e. Distant progression free survival

Fig. 1. Kaplan–Meier’s curves of survival by baseline dNLR.
| Variable | Category | Time (months) | Univariable | Multivariable |
|----------|----------|---------------|-------------|---------------|
|          |          | n | Median | 95% CIs | HR | 95% CIs | p | HR | 95% CIs | p |
| dNLR     | dNLR < 2 | 146 | 36.0  | 27.8–42.4 | 1.00 | 1.00  | 1.00 | 1.00 |
|          | dNLR ≥ 2| 111 | 18.4  | 14.1–24.9 | 1.74 | 1.29–2.35 | <0.001 | 1.64 | 1.17–2.29 | 0.004 |
| Trial arm| CRT only | 129 | 34.5  | 24.7–42.3 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | CRT + cetuximab | 129 | 24.7  | 18.6–31.3 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Age      | <65      | 109 | 36.7  | 24.9–43.6 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | ≥65      | 149 | 24.5  | 19.7–30.1 | 1.36 | 1.00–1.85 | 0.047 | 1.27 | 0.91–1.77 | 0.156 |
| Reason no surgery | Patient choice | 97 | 31.3  | 24.0–44.0 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | Local extent of disease | 122 | 24.7  | 18.6–34.5 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | Comorbidity/Poor PS | 39 | 31.6  | 14.8–42.7 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Sex      | Female   | 113 | 34.6  | 24.7–48.8 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | Male     | 145 | 24.9  | 19.6–31.6 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| WHO status | 0 | 131 | 30.3  | 24.0–38.4 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | 1        | 127 | 24.9  | 19.2–34.3 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Stage    | I or II  | 103 | 42.4  | 31.3–49.9 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | III      | 155 | 24    | 18.6–26.8 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Tumour type | Squamous | 188 | 28.4  | 24.0–38.0 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | Adeno/undiff | 70 | 24.9  | 15.9–35.1 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Full radiation dose | Yes | 217 | 34.3  | 25.8–39.1 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | No       | 41  | 10    | 5.9–18.4 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Cisplatin intensity | ≥75% | 182 | 35.9  | 27.2–42.4 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | <75%     | 76  | 16.2  | 12.5–20.8 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Cape/5FU intensity | ≥75% | 172 | 34.5  | 25.4–39.4 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | <75%     | 86  | 20    | 15.4–24.7 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
| Total disease length | <4 cm | 56  | 36    | 24.7–58.0 | 1.25 | 0.93–1.69 | 0.137 | 1.18 | 0.86–1.61 | 0.318 |
|          | ≥4 to <6 cm | 85 | 37.9  | 24.0–49.9 | 0.98 | 0.63–1.52 | 0.928 | 1.07 | 0.67–1.71 | 0.768 |
|          | ≥6 to <8 cm | 55 | 24.9  | 18.6–40.3 | 1.46 | 0.92–2.33 | 0.107 | 1.13 | 0.67–1.92 | 0.638 |
|          | ≥8 cm    | 62  | 18.4  | 14.9–27.8 | 1.84 | 1.17–2.89 | 0.009 | 1.37 | 0.94–2.62 | 0.123 |

**Table 2**
Univariable and multivariable Cox regression analysis of overall survival.

**Table 3**
Effect of dNLR in predicting treatment effect.

**Fig. 2.** Kaplan–Meier’s curves of SCOPE1 treatment by dNLR.
studies, and would suggest that this is a useful baseline variable for assessing prognosis in oesophageal cancer patients being considered for dCRT.

The major implication of dNLR would be to risk-stratify patients, assisting the clinician and patient to make an informed decision about treatment options. For example, in patients who are borderline fit for dCRT, it is often difficult to quantify potential benefits of a given treatment versus the real risk of significant and potentially life-threatening toxicities. Discussions using pre-treatment dNLR results may assist the individual patient to weigh up whether the side-effects of dCRT are worth risking, particularly if they are considered to have a poor prognosis as determined by a raised pre-treatment dNLR, or whether they would prefer to employ a more conservative treatment strategy. Given the variation in survival, consideration should also be given to use dNLR as a stratification factor for future dCRT trials.

The strengths of this current study is that the data were prospectively collected, setting in the context of a randomised controlled trial which has now standardised treatment of oesophageal cancer with dCRT in the UK. dNLR was available for all patients within one week of starting treatment in the patients included in our analysis. However, the dNLR cut-off value found in this study will need to be validated in further independent datasets. Whilst this study has validated pre-treatment dNLR as a potential prognostic biomarker for oesophageal cancer patients treated with dCRT, analysis of other haematological components, albumin and other markers of the systemic inflammatory response such as C-reactive protein (CRP) was not conducted.

In conclusion, we have demonstrated that an elevated pre-treatment dNLR is a potential independent prognostic marker for both OS and PFS in oesophageal cancer treated with dCRT. It serves as a readily available tool for risk-stratifying patients and should be considered as a stratification factor in future clinical trials aiming to optimise non-surgical treatment strategies for locally-advanced oesophageal cancer.

Conflict of interest statement

Samantha Cox has received educational sponsorship from Merck Serono and Pfizer to attend an international conference. All remaining authors have declared no conflicts of interest.

Acknowledgments and funding

Somnath Mukherjee is part-funded by MRC and supported by NIHR Oxford Biomedical Research Centre. The SCOPE1 trial was supported by Cancer Research UK [grant number C20177/A7256].

Merck Serono supplied free cetuximab, drug labeling and distribution in the original SCOPE1 trial but had no role in its design, or in the collection, analysis and interpretation of data. Merck Serono had no involvement in the writing of this manuscript or the decision for submission for publication.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.radonc.2017.08.023.

References

[1] Cancer Research UK. Oesophageal Cancer Survival Statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/survival (Accessed 14/02/17).
[2] Gwynne S, Falk S, Collins S, et al. Oesophageal chemoradiotherapy in the UK—current practice and future directions. Clin Oncol (R Coll Radiol) 2013;25:368–77.
[3] Crosby T, Hurtt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1) a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013;14:627–37.
[4] Mukherjee S, Hurtt C, Falk S, et al. Long term results and patterns of recurrence from SCOPE 1: a phase III/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer. J Clin Oncol 2016;34 (suppl 45; abstr 118).
[5] Cooper JS, Guo MD, Hershkovits A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow up of a prospective randomized trial (RTOG 85 01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–7.
[6] Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1166–8.
[7] Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006:CD002092.
[8] Halabi S, Oezvar K. The importance of identifying and validating prognostic factors in oncology. Semin Oncol 2010;37:e9–e18.
[9] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
[10] Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer 2011;47:2633–41.
[11] McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534–40.
[12] Guthrie GJ, Charles RA, Roxburgh CS, et al. The systemic inflammation-based neutrophil–lymphocyte ratio experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218–30.
[13] Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors a systematic review and meta-analysis. J Natl Cancer Inst 2014;106: dju124.
[14] Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012;107:695–9.
[15] Hurtt CN, Nixon LS, Griffiths GO, et al. SCOPE1: a randomised phase III/II multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the esophagus. BMC Cancer 2011;11:466.
[16] Loibl S, Skael K, Nekljudova V, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer – a pooled analysis. BMC Cancer 2011;11:131.
[17] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073–81.
[18] Krenn-Pilko S, Langenslechner U, Stojakovic T, et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumour Biol 2016;37:361–8.
[19] van Soest RJ, Templeton A, Vera-Badillo F, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 2015;26:743–9.
[20] Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395–400.
[21] Szkandera J, Stotz M, Eissner F, et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One 2013;8:e78225.
[22] Zou Q, He B, Liu X, et al. Prognostic value of preoperative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med 2015;13:66.
[23] Grenader T, Nash S, Plotkin Y, et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Ann Oncol 2015;26:1910–6.
[24] Yodberg H, Matsuda A, Miyashita M, et al. prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:646–54.
[25] Yoo EJ, Park JC, Kim EH, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Dig Liver Dis 2014;46:846–53.